Evidence map›Paper›PMID 40676576›Full record

ArticleBMC endocrine disorders2025

Incretin-based approaches for type 2 diabetes therapy: effects on circulating cytokines and adipocyte's secretome.

Margarita Agareva, Svetlana Michurina, Alina Tomilova, Ekaterina Shestakova, Anastasia Voznesenskaya, Maria Sineokaya, Ekaterina Zubkova, Elizaveta Ratner, Iurii Stafeev, Yelena Parfyonova and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Margarita AgarevaNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia.
Svetlana MichurinaNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia.
Alina TomilovaEndocrinology Research Centre, Moscow, 117292, Russia.
Ekaterina ShestakovaEndocrinology Research Centre, Moscow, 117292, Russia.
Anastasia VoznesenskayaEndocrinology Research Centre, Moscow, 117292, Russia.
Maria SineokayaEndocrinology Research Centre, Moscow, 117292, Russia.
Ekaterina ZubkovaNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia.
Elizaveta RatnerNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia.
Iurii StafeevNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia. yuristafeev@gmail.com.
Yelena ParfyonovaNational Medical Research Centre of Cardiology named after academician E.I.Chazov, Moscow, 121552, Russia.
Marina ShestakovaLomonosov Moscow State University, Moscow, 119991, Russia.

Funding

Russian Science Foundation 22-15-00365-П
6 · The paper itself

Abstract

backgroundAdipose tissue secretome plays a crucial role in the mechanisms of metabolic diseases. Weight loss has a favourable effect on the adipose tissue secretome and prevents the development of type 2 diabetes mellitus (T2DM) and its complications. The most effective methods of glycaemic control are bariatric surgery (BS) and pharmacotherapy. The aim of our study is to evaluate changes in adipose tissue secretome after BS and semaglutide injections.

methods17 patients with T2DM were examined before and 6 months after BS or semaglutide therapy. The examination protocol included anthropometry, clinical biochemistry, insulin resistance evaluation and collection of subcutaneous adipose tissue biopsies. Adipose derived stem cells (ADSC) were isolated from biopsies according to a standard enzymatic protocol and differentiated into white and beige adipocytes. Adipogenesis and thermogenesis were assessed by confocal microscopy. Secretome of adipocytes and cytokines plasma levels were analyzed using a MILLIPLEX panel.

resultsFollowing BS and semaglutide therapy, a decline in BMI, total fat content, HbA1c, and fasting blood glucose was observed. Insulin sensitivity increased only 6 months after BS. Semaglutide therapy resulted in the elevation of angiogenic and proinflammatory cytokines in adipocyte secretory profile. After BS we also detected the increase in proinflammatory cytokines both in adipocyte secretome and in plasma levels. However, the adipocyte secretome subsequent to bariatric surgery (BS) exhibited a reduced proinflammatory response in comparison to that observed following semaglutide therapy.

conclusionsThe effect of semaglutide injections directly on adipose tissue can change the function of ADSC, making them more angiogenic and adipogenic. A decrease in BMI, HbA1c and insulin resistance is achieved to a significant extent only after BS. BS-induced T2DM remission is related to lower pro-inflammatory secretion from adipocytes as compared to semaglutide. The regulation of inflammation in adipocytes may serve as a potential mechanism underlying BS-induced T2DM remission.

Indexed as

AdipocytesCytokinesDiabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsIncretinsSecretomeAdultBariatric SurgeryFemaleFollow-Up StudiesGlucagon-Like Peptide 1HumansInsulin ResistanceMaleMiddle AgedCytokinesGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsIncretinsSemaglutideAdipocytesAdipose-derived stem cellsCytokinesPlasmaSecretomeType 2 diabetes

Identifiers

PMID40676576
PMCPMC12269230

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.